United States Patent 9,326,947: Scope, Claim Boundaries, and US Patent Landscape
What does US 9,326,947 claim in plain scope terms?
US 9,326,947 claims an oral, soft-gel-type fumarate ester formulation and a manufacturing method centered on a specific lipid/lipophilic matrix system and fumarate ester loading/distribution.
Core claimed invention (independent claim 1)
Claim 1 is the foundation. It covers:
- Dosage form: “An oral pharmaceutical composition”
- Active(s): “one or more fumarate esters”
- Explicitly reads on dimethyl fumarate (DMF) and monomethyl fumarate (MMF) in dependent claims
- Matrix: a lipid or lipophilic vehicle that contains a defined mixture of:
- mono- and di-glycerides
- polyvinylpyrrolidone (PVP)
- polyoxyl 40 hydrogenated castor oil (commonly referred to as HCO-40, Cremophor RH40-type excipient)
- Loading relationship (key ratio):
- fumarate ester : matrix = about 1:1 to about 1:5
- Matrix composition constraints (explicitly quantified later in claim 4 and examples-like claim 6)
Claim 1 does not limit:
- Therapeutic indication (it is composition/formulation driven)
- Specific capsule type until later claims
- Exact particle size unless dependent claim 11 applies
Key limitation stack in dependent claims
The claim set narrows through multiple “layers”:
Actives
- Claim 2: fumarate ester is DMF, MMF, or both
- Claims 12-13: DMF or MMF individually
Optional acid component
- Claim 3: matrix further comprises lactic acid
- Claims 5 and 7: define lactic acid ranges that tie to specific formulation embodiments
Quantified composition ranges
- Claim 4 gives general % ranges:
- 20% to 50% fumarate esters
- 18% to 70% mono- and di-glycerides
- 1% to 10% PVP
- 2% to 12% polyoxyl 40 hydrogenated castor oil
- Claim 6 gives a narrower exemplar-like composition:
- 28% fumarate esters
- 54% mono- and di-glycerides
- 3% PVP
- 10% polyoxyl 40 hydrogenated castor oil
These dependent claims matter because they define literal infringement boundaries for formulations that otherwise might meet the conceptual claim 1 matrix.
Fumarate dose amount per composition
- Claim 8: fumarate esters amount about 100 mg to 230 mg
- Claim 9: 100 mg to 115 mg
- Claim 10: 200 mg to 230 mg
This converts the claim from a purely ratio-based concept to dose-range-specific coverage.
Particle size
- Claim 11: milled/micronized fumarate esters with PSD d90 ≤ 100 μm
This is a strong manufacturing/process-driven limitation that can materially narrow practical read-across to products with different milling specs.
Technical performance/property limitations
- Claim 14: prevents sublimation during manufacturing
- Claim 15: reduces flushing or gastrointestinal side effects
- Claim 16: stable ≥ 1 year at 25°C
These are functional/product-performance statements that can still be infringed if the accused product achieves the same outcome under claim interpretation standards. They are less “design-around friendly” than purely compositional terms, but they can be used as leverage in claim construction and noninfringement arguments.
Capsule format (soft capsules)
- Claim 17: encapsulated in a soft capsule
- Claim 18: encapsulated in an enteric soft capsule
This connects the matrix to a specific delivery system typical of marketed fumarate ester capsule products designed to manage gut release and reduce local irritation.
What does US 9,326,947 claim about manufacturing (method coverage)?
Claim 19 is a method for manufacturing that is tied to both materials and equipment steps, then flows into an apparatus-like encapsulation process.
It covers:
- Provide a lipid or lipophilic matrix fill:
- suspension of fumarate esters
- fumarate ester : matrix = 1:1 to 1:5
- matrix includes mono-/di-glycerides + PVP + polyoxyl 40 hydrogenated castor oil
- Provide soft capsule shell composition
- Cast shell films using heat-controlled drums/surfaces
- Form the soft capsule using rotary die encapsulation technology
Claim 20 then captures the resulting product:
- “A pharmaceutical composition comprising a soft capsule shell encapsulating a lipid/lipophilic matrix comprising fumarate esters produced by the method of claim 19.”
So infringement can be pursued either:
- directly as a product formulation (claims 1-18), and/or
- as a product-by-process if the method is followed (claims 19-20).
What is the scope perimeter for literal infringement?
The claim set is broad at claim 1’s concept level but narrow in practice due to multiple mandatory constraints. A product likely needs to satisfy at least these “hard gates” to fall in:
Hard gates (most likely required)
- Fumarate esters as active (DMF/MMF covered expressly)
- Oral administration
- Matrix contains:
- mono- and di-glycerides
- PVP
- polyoxyl 40 hydrogenated castor oil
- Ratio fumarate ester : matrix between 1:1 and 1:5
Likely additional gates depending on the accused product
- Lactic acid present if asserting claims 3/5/7
- Weight % ranges if asserting claims 4/6
- Exact dose range (100-115 mg or 200-230 mg) if asserting claims 8-10
- Particle size d90 ≤ 100 μm if asserting claim 11
- Enteric soft capsule if asserting claim 18
- Manufacturing equipment/process if asserting claim 19 or product-by-process claim 20
How should competitors read the dependent-claim architecture for design-around?
The landscape implications are driven by where the claims are composition-anchored versus property/process-anchored.
Design-around pressure points
-
Matrix excipient selection
- Claim 1 requires a specific three-component vehicle combination (mono-/di-glycerides + PVP + polyoxyl 40 hydrogenated castor oil).
- If an accused product substitutes one component, it risks leaving claim 1’s literal scope.
-
Loading ratio
- Claim 1’s 1:1 to 1:5 ratio is a clear numeric boundary. Reformulation outside this range is a direct design-around route.
-
Particle size
- If the fumarate esters are not milled to d90 ≤ 100 μm, claim 11 may not read.
-
Soft capsule architecture
- Standard soft capsules may implicate claim 17, but enteric soft capsules are needed for claim 18.
-
Manufacturing method tied to rotary die encapsulation
- Non-rotary die encapsulation or materially different film casting steps can be a method design-around for claim 19.
Where design-around is harder
- Performance statements like anti-sublimation, side-effect reduction, and 1-year stability can be met by many formulations and can be argued as inherent or achieved outcomes, depending on evidence standards.
What is the US patent landscape likely to look like around this claim family?
Given the claim content (fumarate esters, soft capsules, mono-/di-glycerides, PVP, polyoxyl 40 hydrogenated castor oil, lactic acid, anti-sublimation, PSD limits, rotary die encapsulation), the relevant landscape in the US typically clusters into three patent “lanes”:
- Formulation patents for fumarate ester stability and tolerability (excipient packages, particle size, and ratio/loading)
- Capsule/encapsulation patents (soft/enteric soft capsule structures and process manufacturing steps, including rotary die encapsulation)
- API specification and physical form patents (milling/micronization specs and solid-state properties)
However, the user-provided prompt does not include the patent’s title, assignee, filing date, priority data, prosecution history, or citation list, so an evidence-backed map of:
- which assignees hold the closest US-family members,
- which patents are most relevant by claim overlap,
- what the active expiration timelines and terminal disclaimers are,
cannot be constructed from the supplied text alone.
Accordingly, the analysis below focuses on claim-scope-to-landscape mapping rather than naming specific overlapping US patents.
Claim-to-landscape overlap map (actionable for FTO scoping)
1) “Fumarate ester in mono-/di-glyceride + PVP + HCO-40” matrix
This is the central formulation “signature.” In landscape terms, any competing product that uses a different surfactant/emulsifier system (or omits PVP) will likely avoid claim 1.
FTO implication: request product excipient disclosure and manufacturing formulation records for:
- PVP presence and grade
- exact emulsifier/surfactant identity matching “polyoxyl 40 hydrogenated castor oil”
- mono-/di-glyceride type and composition
- achieved fumarate ester-to-matrix ratio
2) Ratio constraint 1:1 to 1:5
This is an easily testable numeric boundary.
FTO implication: compare:
- fumarate ester weight fraction vs total matrix weight fraction used in the capsule fill
- whether “matrix” includes PVP and HCO-40 fully in the same denominator used by the claim language
3) Lactic acid as optional component
This becomes a fork: a competitor may include lactic acid for tolerability/stability, but claim coverage changes if they omit it.
FTO implication: treat lactic acid as a “must match” parameter when assessing dependent claims 3/5/7.
4) PSD d90 ≤ 100 μm
This introduces an analytical/solid-state manufacturing axis.
FTO implication: evaluate particle size distributions from:
- incoming API micronization data
- final blend d90 if measured
- any process that preserves larger PSD
5) Soft capsule and enteric soft capsule
Competing products that are tablets or hard capsules are farther from scope.
FTO implication: confirm:
- dosage form type
- whether the soft capsule shell is explicitly enteric
6) Rotary die encapsulation method
This is a process anchor.
FTO implication: compare manufacturing line details:
- encapsulation technology platform
- whether film casting uses “heat-controlled drums or surfaces” and matches the described step structure
Key Takeaways
- US 9,326,947’s independent claim 1 is a soft oral fumarate ester formulation defined by a specific lipid/lipophilic matrix containing mono-/di-glycerides + PVP + polyoxyl 40 hydrogenated castor oil, with fumarate ester:matrix ratio 1:1 to 1:5.
- The most decisive literal boundaries are matrix composition and ratio; dependent claims add lactic acid, percent ranges, dose amounts, PSD d90 ≤ 100 μm, and soft vs enteric soft capsule.
- The patent also claims manufacturing using rotary die encapsulation technology with heat-controlled film casting steps, and captures the resulting product via product-by-process.
- The landscape relevance concentrates in the fumarate formulation + soft capsule lane; excipient swaps, ratio shifts, particle size changes, and alternative encapsulation technologies are the most direct design-around vectors.
FAQs
-
Is dimethyl fumarate explicitly covered?
Yes. Dimethyl fumarate is expressly included in dependent claim 12, and covered generally in claim 2.
-
What is the single most important numeric limitation in claim 1?
The fumarate ester to matrix weight ratio: about 1:1 to about 1:5.
-
Do the claims require lactic acid?
No. Lactic acid is optional in claim 3, with dependent claims specifying ranges in claims 5 and 7.
-
Does the patent cover particle size controlled fumarate esters?
Yes. Claim 11 requires milled or micronized particles with PSD d90 ≤ 100 μm.
-
Is the encapsulation method and resulting product claimed?
Yes. Claim 19 covers a manufacturing method with rotary die encapsulation, and claim 20 covers the resulting soft capsule composition “produced by” that method.
References
- US Patent 9,326,947 (claims as provided in prompt).
